Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
1983-4-7
|
pubmed:abstractText |
We studied the effects of the bile acid sequestrant cholestyramine, alone and in combination with the experimental agent compactin (ML-236B), a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on serum levels of lipoproteins in 10 heterozygous patients with familial hypercholesterolemia. After cholestyramine treatment alone for 2 to 16 months, serum total and low-density lipoprotein cholesterol decreased by 20 and 28 per cent, respectively. With the addition of compactin for 12 weeks there was a 39 per cent total decrease in serum cholesterol from the control value--from 356 +/- 14 to 217 +/- 10 mg per deciliter (9.27 +/- 0.36 to 5.64 +/- 0.26 mmol per liter [mean +/- S.E.M.]; P less than 0.001)--and a 53 per cent decrease in low-density lipoprotein cholesterol--from 263 +/- 13 to 125 +/- 10 mg per deciliter (6.84 +/- 0.34 to 3.25 +/- 0.26 mmol per liter; P less than 0.001). High-density lipoprotein cholesterol, which had increased during cholestyramine treatment, remained at its higher level. No adverse effects were observed. If long-term safety can be demonstrated, the compactin-cholestyramine regimen may prove useful in heterozygous familial hypercholesterolemia. prove useful in heterozygous familial hypercholesterolemia.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anticholesteremic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol,
http://linkedlifedata.com/resource/pubmed/chemical/Cholestyramine Resin,
http://linkedlifedata.com/resource/pubmed/chemical/Lovastatin,
http://linkedlifedata.com/resource/pubmed/chemical/Naphthalenes,
http://linkedlifedata.com/resource/pubmed/chemical/Phospholipids,
http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides,
http://linkedlifedata.com/resource/pubmed/chemical/compactin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0028-4793
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
17
|
pubmed:volume |
308
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
609-13
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:6828091-Adult,
pubmed-meshheading:6828091-Anticholesteremic Agents,
pubmed-meshheading:6828091-Cholesterol,
pubmed-meshheading:6828091-Cholestyramine Resin,
pubmed-meshheading:6828091-Drug Evaluation,
pubmed-meshheading:6828091-Drug Therapy, Combination,
pubmed-meshheading:6828091-Female,
pubmed-meshheading:6828091-Heterozygote,
pubmed-meshheading:6828091-Humans,
pubmed-meshheading:6828091-Hyperlipoproteinemia Type II,
pubmed-meshheading:6828091-Lovastatin,
pubmed-meshheading:6828091-Male,
pubmed-meshheading:6828091-Middle Aged,
pubmed-meshheading:6828091-Naphthalenes,
pubmed-meshheading:6828091-Phospholipids,
pubmed-meshheading:6828091-Triglycerides
|
pubmed:year |
1983
|
pubmed:articleTitle |
Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
|
pubmed:publicationType |
Journal Article
|